SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20784)5/14/1998 3:14:00 PM
From: dwc  Respond to of 32384
 
Shares of SUGEN are up 8% today. I think this is the other cancer drug being discussed in media.



To: Henry Niman who wrote (20784)5/14/1998 3:31:00 PM
From: Hippieslayer  Respond to of 32384
 
The delay of the forum is probably why lgnd has been so weak. :)



To: Henry Niman who wrote (20784)5/14/1998 3:36:00 PM
From: Pseudo Biologist  Read Replies (1) | Respond to of 32384
 
Henry, you may be interested to know that Novartis drug Simulect was given formal approval by the FDA as per today's issue of "BioWorld." As discussed here, Seragen will receive royalties on sales of this product. From the 10-K of Seragen's, it appears that these royalty payments will amount to 0.75% (not clear if of gross or net sales?) and will begin in 2001.

Here is a link to the news:

biz.yahoo.com

Sorry to be sort of "on-topic" -gg-

PB


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News